Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 20:12:61-71.
doi: 10.2147/JEP.S240266. eCollection 2020.

Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice

Niguse Meles Alema  1   2 , Gomathi Periasamy  2 , Gereziher Gebremedhin Sibhat  2 , Gebretsadkan Hintsa Tekulu  2 , Mebrahtom Gebrelibanos Hiben  2
Affiliations

Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice

Niguse Meles Alema et al. J Exp Pharmacol. .

Abstract

Background: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal candidates. Hence, this study was undertaken to investigate the antidiabetic activity of crude extract and solvent fractions from the stem bark of Terminalia brownii Fresen. (Combretaceae) in mice.

Materials and methods: The in vitro α-amylase inhibition assay was performed using the chromogenic 3, 5-dinitrosalicylic acid (DNSA) method while the antihyperglycemic activity was assessed using three mouse models: streptozotocin-induced diabetic mice, normoglycemic mice, and oral glucose challenged mice. Experimental diabetes was induced by a single intraperitoneal injection of streptozotocin at a dose of 150 mg/kg and animals with fasting blood glucose level (BGL) >200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a standard drug. Fasting BGL and body weight were used to assess the antidiabetic activity. The result was analyzed using GraphPad Prism software version 8 and one-way ANOVA followed by Tukey's post hoc test with p<0.05 considered as statistically significant.

Results: The crude extract of T. brownii at all tested dose levels (250, 500 and 750 mg/kg) showed a significant BGL reduction in all the three animal models. Moreover, the ethyl acetate and aqueous fractions (at 500 mg/kg) significantly (p<0.01) reduced the BGL in the streptozotocin induced diabetic model. The crude extract and different solvent fractions also showed a dose-dependent in vitro α-amylase inhibitory activity and improvement of body weight.

Conclusion: T. brownii crude extract and its solvent fractions showed a significant antihyperglycemic activity in STZ induced diabetic mice, hypoglycemic activity and improvement of oral glucose tolerance in normal mice.

Keywords: diabetes mellitus; medicinal plant; streptozotocin; α-amylase.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Plot of % α-amylase inhibition of the crude extract and solvent fractions vs concentration. Abbreviations: AF, aqueous fraction; BF, butanol fraction; CF, chloroform fraction; EAF, ethyl acetate fraction.
See this image and copyright information in PMC

References

    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med. 1998;15(7):539–553. doi:10.1002/(ISSN)1096-9136 - DOI - PubMed
    1. Deshmukh CD, Jain A. Diabetes mellitus: a review. Int J Pure Appl Biosci. 2015;3:224–230.
    1. Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011;2(9):1000167.
    1. Hall V, Thomsen RW, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999–2011: epidemiology and public health implications. A systematic review. BMC Public Health. 2011;11(1):564. doi:10.1186/1471-2458-11-564 - DOI - PMC - PubMed
    1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi:10.1016/j.diabres.2017.03.024 - DOI - PubMed

LinkOut - more resources